Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - SECOND SIGHT MEDICAL PRODUCTS INC | ex_124109.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): September 15, 2018
|
SECOND SIGHT MEDICAL PRODUCTS, INC. |
|||||
|
(Exact Name of Registrant as Specified in Its Charter) |
|||||
|
|
|||||
|
California |
|||||
|
(State or Other Jurisdiction of Incorporation) |
|||||
|
|
|||||
|
|
333-198073 |
|
|
02-0692322 |
|
| (Commission File Number) | (IRS Employer Identification No.) | ||||
|
|
|
||||
|
|
12744 San Fernando Road, Suite 400 |
|
|||
| (Address of Principal Executive Offices) | |||||
|
|
|||||
|
(818) 833-5000 |
|||||
|
(Registrant's Telephone Number, Including Area Code) |
|||||
|
(Former Name or Former Address, if Changed Since Last Report) |
|||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 8.01. Other Events.
On September 15, 2018, Second Sight Medical Products, Inc. (the “Company”) received a Notice of Award from the National Institutes of Health (“NIH”) for grant 1UH3NS103442-01. The Company has received a $1.6 million grant (with intent to fund $6.3 million over five years subject to annual review and approval) from the NIH to fund the “Early Feasibility Clinical Trial of a Visual Cortical Prosthesis”.
On September 18, 2018, the Company issued a press release entitled “Second Sight Receives $1.6 Million Grant from National Institutes of Health to Support Orion Clinical Development”. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No. |
Description |
|
99.1 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: September 18, 2018
SECOND SIGHT MEDICAL PRODUCTS, INC.
| /s/ John T. Blake | ||
| By: John T. Blake | ||
| Chief Financial Officer |
-2-